Consolidation With Campath-1H After FMC Induction in Patients With T-Cell Chronic Lymphocytic Leukemia
- Determine the number of severe adverse events and life-threatening infections in
patients with T-cell chronic lymphocytic leukemia or T-cell prolymphocytic leukemia
treated with induction chemotherapy comprising fludarabine, cyclophosphamide, and
mitoxantrone hydrochloride followed by consolidation therapy comprising alemtuzumab.
- Determine the remission rate in patients treated with this regimen.
- Determine the overall and progression-free survival of patients treated with this
- Determine the quality of remission in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients receive induction chemotherapy comprising fludarabine IV and cyclophosphamide IV
for 3 days and mitoxantrone hydrochloride IV on 1 day. Treatment repeats every 28 days for
up to 4 courses. Patients then receive consolidation therapy comprising alemtuzumab IV 3
times in week 1 and then weekly for up to 11 weeks.
PROJECTED ACCRUAL: A total of 17 patients will be accrued for this study.
Masking: Open Label, Primary Purpose: Treatment
Adverse effects at 2 months after treatment
United States: Federal Government